Document zzzgLx3oJKy0Nk9aZvrBexZY7

AR226-3147 DuPont-3823 TRADE SECRET Study Title H-24335: Local Lymph Node Assay (LLNA) Laboratory Project ID: DuPont-3823 AUTHOR: Gregory S. Ladies, PhD ., D.A.B.T. Study Com pleted on: April 28,2000 P erform ing L aboratory: E. I. du Pont de Nemours and Company Haskell Laboratory for Toxicology and Industrial Medicine Elkton Road, P.O. Box 50 Newark, Delaware 19714-0050 Work Request Number:|| ) Service Code Number^ 1 Company Sanitized. Does not contain TSCA CB1 H-24335: Local Lymph Node Assay (LLNA) DuPont-3823 CERTIFICATION I, the undersigned, declare that this report provides an accurate evaluation of data obtained from this study. Issued by Study Director: cLh/' sgory S. Ladies, Ph.D., D.A.B.T. Senior Research Scientist Date Company Sanitized. Does not contain TSCA CBf -2 - H-24335: Local Lymph Node Assay (LLNA) DuPont-3823 TABLE OF CONTENTS Page CERTIFICATION................................................................................................................................ 2 LIST OF TABLES................................................................................................................................ 3 STUDY INFORMATION................................................................................................................... 4 STUDY PERSONNEL.........................................................................................................................5 S U M M A R Y ........................................................................................................................................... 6 INTRODUCTION.............................................................................. 7 MATERIALS AND METHODS........................................ 7 A. Test Species.............................................................................................................................. 7 B . Body Weight Measurements.................................................................................................... 7 C. Test Substance.......................................................................................................................... 7 D. Clinical Observations................................................................................................................7 E. Local Lymph Node A ssay....................................................................................................... 8 F. Statistical Analyses...................................................................................................................8 RESULTS AND DISCUSSION..........................................................................................................9 A. Clinical Signs of Toxicity, Body Weights, and Body Weight Gains.................................... 9 B. Stimulation Index D ata.............................................................................................................9 CONCLUSIONS.................... .'................................... ...9 RECORDS AND SAMPLE STORAGE.............................................................................................9 REFERENCES................................................................................................................................. ...10 T A B L E S ............................................................................................... 11 LIST OF TABLES Page TABLE 1 MEAN BODY WEIGHTS(g)...........................................................................................12 TABLE 2 MEAN BODY WEIGHT GAINS(g)............................................................................... 12 TABLE 3 STIMULATION INDEX (SI) DATA................................ 13 Company Sanitized. Does not contain TSCA CBt -3 - H-24335: Local Lymph Node Assay (LLNA) STUDY INFORMATION Svnonvms/Codes: H-24335 Haskell Number: 24335 DuPont-3823 Stability: The test substance appeared to be stable under the conditions of the study; no evidence of instability was observed. Sponsor: E. I. du Pont de Nemours and Company Wilmington, Delaware 19898 U.S.A. Study Initiated/Comnleted: January 27, 2000 / (see report cover page) In-Life Initiated/Completed: April 1, 2000 / April 7, 2000 Company Sanitized. Does not contain TSCA CBi H-24335: Local Lymph Node Assay (LLNA) DuPont-3823 STUDY PERSONNEL The following individuals participated in the conduct of this study: Study Director: Gregory S. Ladies, Ph.D., D.A.B.T. Management: Judith C. Stadler, Ph.D., D.A.B.T. Primary Technician: Charlene Smith, S.A. Toxicology Report Preparation: Brenda Tiffin Laboratory Veterinarian: Wanda L. West, D.V.M., A.C.L.A.M. Company Sanitized. Does not contain TSCA CB1 -5 - H-24335: Local Lymph Node Assay (LLNA) DuPont-3823 SUMMARY The objective of this study was to evaluate the potential of H-24335 to produce a dermal sensitization response in mice using the local lymph node assay (LLNA). Six groups of female CBA/JHsd mice were dosed for 3 days with 0 (vehicle), 5%, 10%, 25%, 50%, or 100% H-24335 on the dorsal side o f both ears. Dimethylsulfoxide was used as the diluting vehicle. A seventh group of 6 female mice was dosed for 3 days with 25% Hexylcinnamaldehyde (HCA) as a positive control. On test day 5 of the assay, mice received 3-H-Thymidine by tail vein injection and were sacrificed 5 hours later. The cell proliferation in the draining auricular lymph nodes of the ears was then evaluated and compared to control. There were no clinical signs of toxicity observed in the study. There were no statistically significant differences in mean body weights and mean body weight gains between the vehicle control group and any test substance group. No statistically significant differences were seen in cell proliferation measurements at any test concentration. Stimulation indexes were less than 3.0 at all concentrations. A 25% concentration of the positive control, HCA, produced a positive dermal sensitization response in mice. Therefore, the LLNA test system was valid for this study with H-24335. Under the conditions of this study, H-24335 did not produce a positive dermal sensitization response in mice. Company Sanitized. Does not contain TSCA CB'i -6 - H-24335: Local Lymph Node Assay (LLNA) DuPont-3823 INTRODUCTION The purpose of this study was to examine the dermal sensitization potential of H-24335 using the local lymph node assay (LLNA). Following the topical application of the test article to the dorsal side of both ears, the dermal sensitization potential of the test article was evaluated by measuring the proliferation of lymphocytes (via radiolabel uptake) obtained from the auricular lymph nodes (i.e., the lymph nodes that drain the ears). Because H-24335 is a iH H fL n d did not appear to have severe skin irritating capability (pH ~4-5), the 100% concentranoi^as used as the high dose. For subsequent dilutions, the test article was found to be soluble in dimethlysulfoxide (DMSO). MATERIALS AND METHODS A. Test Species The Local Lymph Node Assay with H-24335 was conducted in female CBA/JHsd mice. On March 16, 2000, 48 female mice, with an assigned birth date of January 28,2000, were received from Harlan Sprague Dawley, Fredrick, Maryland. The CBA/JHsd mouse was selected to conduct the LLNA because Haskell Laboratory has an extensive database with this strain. Furthermore, the strain has undergone extensive interlaboratory validation with the LLNA.(1'3) B. Body Weight Measurements All mice were weighed on test day 0 and prior to sacrifice on test day 5. C. Test Substance The test substance, H-24335, was supplied by the sponsor a s ; m r h e test substance was vortex to mix before each amount for dosing was removed, t he test substance appeared to be stable under the conditions of the study. No evidence of instability, such as a change in color or physical state, was observed. D. Clinical O bservations Cage-site examinations to detect moribund or dead mice and abnormal behavior and appearance among mice were conducted at least once daily throughout the study. At every weighing, each mouse was individually handled and examined for abnormal behavior and appearance. Company Sanitized. Doos no! contain TSCA CB1 -7 - H-24335: Local Lymph Node Assay (LLNA) DuPont-3823 E. Local Lymph Node Assay The test substance was prepared as a solution in DMSO except the 100% concentration. Twenty-five /I of H-24335 was administered topically to the dorsum of each ear o f mice (6 per group) for 3 consecutive days (test days 0-2) at dosages of 0% (DMSO vehicle), 5%, 10%, 25%, 50%, and 100%. One group of 6 female mice was dosed with 25% hexylcinnamaldehyde (HCA) as a positive control. Test days 3-4 were days of rest followed by intravenous injection of 20/tCi of 3H-Thymidine per mouse on the morning of test day 5. One mouse in the 10% concentration group was not properly injected with the appropriate amount of 3H-Thymidine and was excluded from study. Approximately 5 hours later, animals were sacrificed, draining auricular lymph nodes were removed, and single cell suspensions were prepared. The single cell suspensions were then incubated at 2-8C overnight. Disintegrations per minute (dpm) data were obtained on test day 6 by counting the single cell suspensions on a beta counter. A stimulation index (SI) was derived for each experimental group by dividing the mean dpm of the experimental group by the mean dpm of the vehicle control group. Statistical significance in the test article groups compared to control and/or Sis of greater than or equal to 3.0 indicated a positive response. F. Statistical Analyses Significance was judged at p < 0.05 except for dpm data which was judged at p <0.01. Parameter Body Weight Body Weight Gain Lymph Node DPM Datab,c Preliminary Test3 Levene's test(4) for homogeneity and Shapiro-Wilk test(5) for normality"1 Method of Statistical Analysis If preliminary test is If preliminary test is not significant significant One-way Analysis of Kruskal-Wallis test; Variance; followed, followed, with Dunn's with Dunnett's test(7) test and/or Sequential application001 of the Jonckheere-Terpstra trend test0 11 a Preliminary test not required when running only the Jonckheere-Terpstra trend test, b If more than 1 mouse was eliminated from a group, statistics were not done on the data for that group, c Positive control dpm data was not included in the statistical analysis. d If the Shapiro-Wilk test was not significant but Levene's test was significant, a rohust version o f Dunnett's test was used. Company Sanitized. Does not contain TSCA CBI -8 - H-24335: Local Lymph Node Assay (LLNA) DuPont-3823 RESULTS AND DISCUSSION A. Clinical Signs of Toxicity, Body Weights, and Body W eight Gains (Tables 1-2) There were no clinical signs of toxicity observed in the study. There were no statistically significant differences in mean body weights and mean body weight gains between the vehicle control group and any test substance group. B. Stimulation Index Data (Table 3) No statistically significant differences were seen in cell proliferation measurements at any test concentration. Stimulation indexes were less than 3.0 at all concentrations of H-24335. CONCLUSIONS A 25% concentration of HCA produced a positive dermal response in mice. Therefore, the LLNA test system was valid for this study with H-24335. Under the conditions of this study, H-24335 did not produce a positive dermal sensitization response in mice. RECORDS AND SAMPLE STORAGE The raw data, and the final report will be retained at Haskell Laboratory, Newark, Delaware, or at Iron Mountain Records Management, Wilmington, Delaware. Company Sanitized. Does not contain TSCA CB! -9 - H-24335: Local Lymph Node Assay (LLNA) DuPont-3823 REFERENCES 1. Loveless, S.E., Ladies, G.S., Gerberick, G.F., Ryan, C.A., Basketter, D.A., Scholes, E.W., House, R.V., Hilton, J., Dearman, R.J., and Kimber, I. (1996). Further Evaluation of the Local Lymph Node Assay in the Final Phase of an International Collaborative Trial. Toxicology 108,141-152. 2. Kimber, I., Hilton, J., Dearman, R.J., Gerberick, G.F., Ryan, C.A., Basketter, D.A., Scholes, E.W., Ladies, G.S., Loveless, S.E., House, R.V., and Guy, A. (1995). An International Evaluation of the Murine Local Lymph Node Assay and Comparison of Modified Procudures. Toxicology 103,63-73. 3. Kimber, I., Hilton, J., Dearman, RJ., Gerberick, G.F., Ryan, C.A., Basketter, D.A., Lea, L., House, R.V., Ladies, G.S., Loveless, S.E., and Hastings, K.L. (1998). Assessment of The Skin Sensitization Potential of Topical Medicaments Using The Local Lymph Node Assay: An Inter-Laboratory Exercise. J. Toxicol. Environ. Health, P a rt A 53(7), 563-579. 4. Levene, H. (1960). Robust test for equality of variances. In Contributions to Probability and Statistics (I. Olkin, ed.), pp 278-292. Stanford University Press, Palo Alto, CA. 5. Shapiro, S.S. and M.B. Wilk, (1965). An analysis of variance test for normality (complete samples). Biometrika 52, 591-611. 6. Snedecor, G. W. and W. G. Cochran, (1967). Statistical Methods, 6th ed., pp. 246-248,349 352. The Iowa State University Press, Iowa. 7. Dunnett, C.W., (1955). A multiple comparison procedure for comparing several treatments with a control. /. Amer. Statist. Assoc. 50,1096-1121. 8. Kruskal, W.H. and W.A. Wallis, (1952). Use of ranks in one-criterion analysis of variance. J. Amer. Statist. Assoc. 47, 583-621. 9. Dunn, O.J., (1964). Multiple contrasts using rank sums. Technometrics 6,241-252. 10. Selwyn, M. R., (1995). The Use of Trend Tests to Determine a No-Observable-Effect Level in Animal Safety Studies. Journal o f the American College o f Toxicology, 14(2), 158-168. 11. Jonckheere, A. R., (1954). "A Distribution-Free K-Sample Test Against Ordered Alternatives," Biometrika 41,133-145. - 10- Company Sanitized. Does not contain TSCA CBJ H-24335: Local Lymph Node Assay (LLNA) DuPont-3823 TABLES Company Sanitized. Does not contain TSCA CB1 - 11 - H>ct335: Local Lymph Node Assay (LLNA) DuPont-3823 TABLE 1 MEAN BODY WEIGHTS(g) GROUP: CONCENTRATION (%): DAYS ON TEST 0 5 n 0 20.7 (1.4) 21.3 (1.2) IV VI v m X x n XIV 5 10 25 50 100 25* 20.8 (1.3) 20.6 (1.0) 20.4 (1.0) 20.7 (0.9) 20.7 (0.9) 20.4(1.1) 21.4 (0.8) 21.4(0.7) 21.2(1.4) 21.2(0.7) 21.3 (1.0) 21.1 (1.4) Standard deviation is reported in parenthesis. Statistical method: Jonckheere-Terpstra trend test was performed on data. There were no statistically significant differences at p > 0.05 * HCA (positive control). TABLE 2 MEAN BODY WEIGHT GAINS(g) GROUP: CONCENTRATION (%): DAYS ON TEST 0-5 n 0 0.6 (0.4) IV VI v m X x n XIV 5 10 25 50 100 25* 0.6 (0.8) 0.8 (0.5) 0.8 (0.7) 0.5 (0.4) 0.5 (0.4) 0.7 (0.9) Standard deviation is reported in parenthesis. Statistical method: Jonckheere-Terpstra trend test was performed on data. There were no statistically significant differences at p > 0.05 * HCA (positive control). Company Sanit?2ed Does not contain TSCACBi H-24335: Local Lymph Node Assay (LLNA) DuPont-3823 TABLE 3 STIMULATION INDEX (SI) DATA GROUP - n IV VI vm X xn XIV MATERIAL TESTED 0% (DMSO) 5% H-24335 10% H-24335 25% H-24335 50% H-24335 100% H-24335 25% HCA in DMSO (positive control) n SI 6 N/A 6 0.78 5 1.15 6 1.15 6 1.37 6 1.5 6 3.98* N/A = Not applicable n = Number of animals per group. There were no statistically significant differences at p > 0.01 by Jonckheere-Terpstra trend and Dunnett's Tests. * = DPM Positive control data was not included in the statistical analysis. Company Sanitized. Does not contain TSCA CBl - 13-